HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010.

Abstract
There has been intense interest in developing inhibitors of the sodium channel Nav1.7 because genetic studies have established very strong validation for the efficacy to alleviate both inflammatory and neuropathic pain. This review summarizes patent applications targeting Nav1.7 since 2010 until May, 2014. We have classified the patents into three categories as follows: small molecules with well-defined molecular selectivity among sodium channel isoforms; biologicals with well-defined molecular selectivity; and, small molecules that inhibit Nav1.7 with unknown molecular selectivity. Most of the review is dedicated to small molecule selective compounds.
AuthorsShaoyi Sun, Charles J Cohen, Christoph M Dehnhardt
JournalPharmaceutical patent analyst (Pharm Pat Anal) Vol. 3 Issue 5 Pg. 509-21 (Sep 2014) ISSN: 2046-8962 [Electronic] England
PMID25374320 (Publication Type: Journal Article, Review)
Chemical References
  • NAV1.7 Voltage-Gated Sodium Channel
  • SCN9A protein, human
  • Voltage-Gated Sodium Channel Blockers
Topics
  • Drug Approval (statistics & numerical data)
  • Drug Industry (legislation & jurisprudence)
  • Humans
  • Molecular Structure
  • NAV1.7 Voltage-Gated Sodium Channel (genetics, metabolism)
  • Patents as Topic (statistics & numerical data)
  • Voltage-Gated Sodium Channel Blockers (chemistry, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: